Skip to content

A Clinical study to evaluate the efficacy and safety of bilberries extract capsules (180mg) in the eye health of human adults.

A prospective, randomized, double blind, placebo controlled clinical study to evaluate the efficacy and safety of bilberries extract capsules (180mg) in the eye health of human adults.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2016/05/006976
Enrollment
30
Registered
2016-05-31
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: H119- Unspecified disorder of conjunctiva

Interventions

Intervention1: Bilberry Extract Capsules: Orally in sitting posture, one capsule in each day before breakfast and dinner for 90 days. Control Intervention1: Placebo capsules: Orally in sitting posture

Sponsors

Vidya herbs
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: •Males & Females with age 30â??60 year •Subjects able to provide informed consent. •Patient is willing and able to comply with all trial requirements •Subjects is having at least anyone of the following condition- Eye strain / redness / watering / burning sensation / itching in the eyes / acuity of vision.

Exclusion criteria

Exclusion criteria: •Subject has had the crystalline lens removed from the study eye or has had the crystalline lens removed and replaced with an intraocular lens (IOL) implant in the left eye. •Subject has been clinically diagnosed with cataracts in the study eye. •Subject has had a fluorescence angiogram within the last six months. •Pregnant or lactating women •Subject has undergone a treatment using photodynamic drugs within the last year. •Subject has Type I or II diabetes or is not deemed healthy from Demographic and Health Questionnaire or the comprehensive eye exam. •Subject was fit with contact lens within the last 30 days.

Design outcomes

Primary

MeasureTime frame
â?¢Changes in visual capacity evaluated by standard comprehensive ophthalmic examination (Snellen test). â?¢Changes in eye conditions like Eye strain / redness / watering / burning sensation / itching in the eye. Timepoint: Screening to EOT (Day 90)

Secondary

MeasureTime frame
â?¢ Incidence and rate of adverse eventsTimepoint: Screening to EOT (Day 90)

Countries

India

Contacts

Public ContactDr Harisha S

ICBio Clinical Research Pvt. Ltd.

harish@icbiocro.com9900111997

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026